Premium
Human recombinant interleukin‐4 inhibits lymphokine‐activated killer activity of sheep erythrocyte rosette‐forming (E + ) and ‐non‐forming (E − ) human lymphocytes
Author(s) -
Gerosa Franca,
Tommasi Marina,
Gerosa Massimo,
Tridente Giuseppe
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910420619
Subject(s) - lymphokine , interleukin 2 , lymphokine activated killer cell , recombinant dna , biology , flow cytometry , immunology , rosette (schizont appearance) , microbiology and biotechnology , natural killer cell , cytokine , immune system , in vitro , cytotoxicity , t cell , interleukin 21 , biochemistry , gene
Abstract The effect of human recombinant interleukin‐4 (rIL‐4) on lymphokine‐activated killer activity (LAK) of peripheral blood lymphocytes (PBL) as well as sheep erythrocyte rosette‐forming (E+) and ‐non‐forming (E–) lymphocytes stimulated by human recombinant interleukin‐2 (rIL‐2) has been investigated. rIL‐4 drastically inhibited LAK activity of PBL cultured for 18 hr and for 5 days in the presence of rIL‐2. Distribution of T, B and IgG Fc‐receptor‐bearing lymphocytes, as assessed by immunofluorescence and flow cytometry, was no different at the end of the culture in the presence of rIL‐2 plus rIL‐4 than with rIL‐2 alone. LAK activity of E+ and E– lymphocytes was similarly inhibited. Finally, rIL‐4 did not affect the natural killer (NK) activity of rIL‐2‐activated PBL as assessed by the capacity of these cells to kill the appropriate NK target.